Piper Sandler has downgraded Q32 (NASDAQ:QTTB) to neutral from overweight, citing the company's decision to discontinue its drug ADX-097 before presenting data from a renal basket study. The ...

Roz Purcell has shared her best advice for fellow alopecia areata sufferers after she revealed 'another bald patch popped up ...

BMO Capital Markets adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotechnology firm's stock rating from Outperform to Market Perform, accompanied by a significant decrease in ...

The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

BMO Capital downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $3, down from $22. The company announced an ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; ...